scholarly journals Effect of Vitamin E on Polycystic Ovary Syndrome Induced by Dehydroepiandrosterone in Female Albino Mice: Histological Study

2021 ◽  
Vol 19 (2) ◽  
pp. 111-130
Author(s):  
Suhera M. Aburawi ◽  
◽  
Soad A. Treesh ◽  
Habiba A. El Jaafari ◽  
Medeha T. El Ghedamsi ◽  
...  
Keyword(s):  
Vitamin E ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Histological Study ◽  
Ovarian Tissue ◽  
Corpora Lutea ◽  
Ovary Syndrome ◽  
Group 4 ◽  
Group 5 ◽  
Group 2

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductiveaged women. Vitamin E is used in combination with clomid, metformin, melatonin or other drugs to ameliorate and improve the symptoms of PCOS. The aim is to investigate the histological effect of vitamin E on PCOS. PCOS model using dehydroepiandrosterone (DHEA) was adopted. Female mice were divided into eight groups (n = 6). Group 1 was administered with 1% T80; Group 2 was administered with DHEA; Group 3 was administered with clomid; Group 4 was administered with vitamin E; Group 5 was administered with DHEA and vitamin E; drugs were administered for 20 days. Group 6 was administered with DHEA per day for 20 days followed by clomid, a dose per day, for the next 10 days; Group 7 was administered with DHEA per day for 20 days followed by vitamin E, a dose per day, for the next 10 days; Group 8 was administered with DHEA every day for 20 days followed by no treatment for the next 10 days. Mice were sacrificed, at the end of experiment, by neck dislocation, ovary was surgically separated and kept in 10% formalin for histological analysis. DHEA administration produces PCOS changes in ovary. Clomid did not improve PCOS induced by DHEA, while vitamin E ameliorates PCOS to nearly normal. Vitamin E showed marked recovery of the ovarian tissue with the presence of many follicles in the various stages of development, indicating normal oogenesis. Follicles showed normal granulosa layer with defined thecal layers. The presence of corpora lutea was also seen, indicating that vitamin E treatment restore normal estrous cycle.

Abnormal expression of uncoupling protein-2 correlates with CYP11A1 expression in polycystic ovary syndrome

2011 ◽  
Vol 23 (4) ◽  
pp. 520 ◽  
Author(s):  
Yun Liu ◽  
Hong Jiang ◽  
Ling-Yun He ◽  
Wu-Jian Huang ◽  
Xiao-Yu He ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Early Stage ◽  
Uncoupling Protein ◽  
Serum Insulin ◽  
Ovarian Tissue ◽  
Fasting Blood Glucose ◽  
Control Group ◽  
Ovary Syndrome ◽  
Protein Levels

Polycystic ovary syndrome (PCOS) may result from hypersensitivity to insulin, which is negatively regulated by uncoupling protein (UCP)-2. Because cholesterol side-chain cleavage enzyme (CYP11A1) is closely linked to PCOS, the expression of UCP-2 and CYP11A1 in ovarian tissues from PCOS patients was examined in the present study. Twelve PCOS patients with hyperandrogenaemia who underwent laparoscopic ovarian wedge resection and 12 age-matched control patients who underwent contralateral ovarian biopsy were enrolled in the study. UCP-2 expression in early stage (primordial, primary and secondary) and late stage (sinus and mature) follicles was examined using immunohistochemistry, whereas UCP-2 and CYP11A1 mRNA and protein levels in ovarian tissue were determined using quantitative reverse transcription–polymerase chain reaction and western blot analyses, respectively. UCP-2 expression increased significantly with follicular development in both control and PCOS tissue, with expression in early stage follicles from PCOS patients significantly greater than that in controls. In addition, both UCP-2 and CYP11A1mRNA and protein levels, mean fasting blood glucose concentrations and fasting serum insulin levels were significantly higher in PCOS patients compared with the control group. Finally, a significant correlation between UCP-2 and CYP11A1 expression was found in PCOS but not control patients. In conclusion, in PCOS patients, there was a correlation between UCP-2 and CYP11A1 expression, which was significantly higher than in the control group. These changes in UCP-2 and CYP11A1 expression may mediate follicle development in PCOS.

Impacts of Metformin on Local Ovarian Cell Tissue of Rats with Polycystic Ovary Syndrome and Intestinal Flora Under Aerobic Exercise

2021 ◽  
Vol 11 (12) ◽  
pp. 2381-2388
Author(s):  
Xiao Yan
Keyword(s):  
Growth Factor ◽  
Polycystic Ovary Syndrome ◽  
Aerobic Exercise ◽  
Polycystic Ovary ◽  
Ovarian Tissue ◽  
Ovary Syndrome ◽  
Ovarian Cell ◽  
Expression Levels ◽  
Cell Tissue ◽  
Igf I

In order to explore the possible treatment mechanism of metformin on the local ovarian cell tissue of rats with polycystic ovary syndrome (PCOS), 35 female clean sterile rats were selected as the research objects in this study, and randomly divided a PCOS model group (PCOS MG) (25 rats) and a control group (CG) (10 rats). After the modelling was completed, 5 rats were randomly selected to evaluate the modelling effect. When the success rate was higher than 80%, the remaining model rats were divided into two groups randomly, namely the (PCOS MG) (10 rats) and the treatment group (TG) (10 rats). Hematoxylin-eosin (HE) staining was performed on ovarian tissue of the rat, and the ovarian tissue structure was observed under light microscope. Immunohistochemistry was used to detect the distribution and expression levels of tumour necrosis factor-α (TNF-α), insulin-like growth factor-I (IGF-I), and connective tissue growth factor (CTGF) on the ovaries of rats in each group. It was found by observing the vaginal smear under the microscope that the rats in the (PCOS MG) had lost the regular estrous cycle, suggesting that there was no ovulation. The expression levels of TNF-α and CTGF in rats in the (PCOS MG) were greatly higher than those in the CG (P < 0.05); compared with the (PCOS MG), the expression levels of TNF-α and CTGF in the TG were decreased observably (P < 0.05). IGF-I was mainly expressed in granulosa cells (GCs) and follicular membrane cells (FMCs) of the ovarian tissue. The expression level of IGF-I in ovarian GCs in rats in the (PCOS MG) was significantly higher than that in the CG (P < 0.05). The expression level of IGF-I in GCs in the TG was lower significantly than that in the (PCOS MG) (P < 0.05). By comparing with rats in the CG, the rats in the (PCOS MG) had obviously decreased Actinobacteria and Betaproteobacteria in the intestinal tract, and the proportion of Firmicutes in the intestine was significantly increased; the amount of butyric acid in the faeces of rats with aerobic exercise was obviously higher than that in the (PCOS MG), because exercise increased the proportion of intestinal butyric acid-producing bacteria. Conclusion: metformin combined with aerobic exercise can treat the PCOS by regulating serum hormone levels and the expression levels of TNF-α, IGF-I, and CTGF.

scholarly journals Autophagy is activated in the ovarian tissue of polycystic ovary syndrome

Reproduction ◽  
2018 ◽  
Vol 155 (1) ◽  
pp. 85-92 ◽  
Author(s):  
Da Li ◽  
Yue You ◽  
Fang-Fang Bi ◽  
Tie-Ning Zhang ◽  
Jiao Jiao ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Potential Role ◽  
Polycystic Ovary ◽  
Ovarian Tissue ◽  
Ovary Syndrome ◽  
Cellular Processes ◽  
Transmission Electron ◽  
Wide Range ◽  
Response To Stress

The importance of autophagy in polycystic ovary syndrome (PCOS)-related metabolic disorders is increasingly being recognized, but few studies have investigated the role of autophagy in PCOS. Here, transmission electron microscopy demonstrated that autophagy was enhanced in the ovarian tissue from both humans and rats with PCOS. Consistent with this, ovarian granulosa cells from PCOS rats showed increases in the autophagy marker protein light chain 3B (LC3B), whereas levels of the autophagy substrate SQSTM1/p62 were decreased. In addition, the ratio of LC3-II/LC3-I was markedly elevated in human PCOS ovarian tissue compared with normal ovarian tissue. Real-time PCR arrays indicated that 7 and 34 autophagy-related genes were down- and up-regulated in human PCOS , Signal-Net, and regression analysis suggested that there are a wide range of interactions among these 41 genes, and a potential network based on EGFR, ERBB2, FOXO1, MAPK1, NFKB1, IGF1, TP53 and MAPK9 may be responsible for autophagy activation in PCOS. Systematic functional analysis of 41 differential autophagy-related genes indicated that these genes are highly involved in specific cellular processes such as response to stress and stimulus, and are linked to four significant pathways, including the insulin, ERBB, mTOR signaling pathways and protein processing in the endoplasmic reticulum. This study provides evidence for a potential role of autophagy disorders in PCOS in which autophagy may be an important molecular event in the pathogenesis of PCOS.

scholarly journals Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth

2014 ◽  
Vol 2014 ◽  
pp. 1-17 ◽  
Author(s):  
Joselyn Rojas ◽  
Mervin Chávez ◽  
Luis Olivar ◽  
Milagros Rojas ◽  
Jessenia Morillo ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovarian Tissue ◽  
Ovary Syndrome ◽  
Main Culprit ◽  
Exact Etiology

Polycystic ovary syndrome (PCOS) is a highly prevalent endocrine-metabolic disorder that implies various severe consequences to female health, including alarming rates of infertility. Although its exact etiology remains elusive, it is known to feature several hormonal disturbances, including hyperandrogenemia, insulin resistance (IR), and hyperinsulinemia. Insulin appears to disrupt all components of the hypothalamus-hypophysis-ovary axis, and ovarian tissue insulin resistance results in impaired metabolic signaling but intact mitogenic and steroidogenic activity, favoring hyperandrogenemia, which appears to be the main culprit of the clinical picture in PCOS. In turn, androgens may lead back to IR by increasing levels of free fatty acids and modifying muscle tissue composition and functionality, perpetuating this IR-hyperinsulinemia-hyperandrogenemia cycle. Nonobese women with PCOS showcase several differential features, with unique biochemical and hormonal profiles. Nevertheless, lean and obese patients have chronic inflammation mediating the long term cardiometabolic complications and comorbidities observed in women with PCOS, including dyslipidemia, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular disease. Given these severe implications, it is important to thoroughly understand the pathophysiologic interconnections underlying PCOS, in order to provide superior therapeutic strategies and warrant improved quality of life to women with this syndrome.

scholarly journals Comparision of Rosiglitazone Maleat Only Use with Combination with Clomiphene Citrate in Infertile Cases with Clomiphen Resistant Polycystic Ovary Syndrome Cases

2021 ◽  
Author(s):  
Sevinç Ünal ◽  
Memet Şimşek
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Statistical Significance ◽  
Clomiphene Citrate ◽  
Pregnancy Rates ◽  
Induction Agent ◽  
Ovary Syndrome ◽  
Insulin Sensitizer ◽  
Group 2 ◽  
Group 1

INTRODUCTION: Most of the obese PCOS patients are resistant to clomiphene citrate standard doses. In these cases metabolic syndromes are treated by using insulin sensitizing drugs so that ovulation can be achieved.In this study rosiglitazine maleat was used in order to induce ovulation in obese clomiphene resistant PCOS patients. METHODS: 30 women(18-40 year old) with clomiphene resistant polycystic ovary syndrome that were obese (BMI>25 kg/m2) and hyperinsulinemic were seperated in two groups. In the first group (n=15) oral antidiabetic Rosiglitazone maleate( 4mg bid) which belongs to thiazolidinediones were used.In the second group(n=15) in addition to clomiphen citrate(50 bid)and Rosiglitazone maleate(4 mg bid) were used, ovulation and pregnancy rates were compared. In both groups ovulation and pregnancy were recorded, in the second group ovulation and pregnancy rates were higher than the first group but these rates were not significant. RESULTS: In group 1, ovulation was achieved in 5 patients (%33) and pregnancy was achieved in 1 patient (%7). In group 2, ovulation was achieved in 9 patients (%60) and pregnancy was achieved in 3 patients (%20).There was no statistical significance between two groups. DISCUSSION AND CONCLUSION: In our study in obese and hyperinsulinemic patients rosiglitazone maleat can induce ovulation and in addition to clomiphene citrate also ovulation can be achieved although it is statistical insignificant. As a result Rosiglitazone maleate can be used alternatively as an insulin sensitizer and ovulation induction agent.

scholarly journals The Value of Serum Adiponectin in Patients with Polycystic Ovary Syndrome

2021 ◽  
pp. 186-197
Author(s):  
Hagar Abd Elrahman Deghaidy ◽  
Mona Khalid Omar Amira Youssef Ahmed ◽  
Elsayed Fetouh Rakha
Keyword(s):  
Polycystic Ovary ◽  
Serum Adiponectin ◽  
Control Group ◽  
Control Groups ◽  
Ovary Syndrome ◽  
Group 4 ◽  
Group 3 ◽  
Obese Control ◽  
Group 2 ◽  
Group 1

Background: Polycystic ovary syndrome (PCOS) is a common condition in women at reproductive age associated with reproductive and metabolic dysfunction. It may be the most common cause of anovulation, early pregnancy loss, and later pregnancy complications. Adiponectin is the most abundant adipokine and is mainly secreted from visceral fat cells. It might be responsible for the metabolic and neuroendocrine derangements characteristic of obesity and obesity-related disease, such as PCOS. We aimed to evaluate the level of serum adiponectin in PCOS and the potential use of adiponectin as a biomarker for PCOS. Methods: This case control study was carried on 100 patients, aged between 20–35 years, who were equally divided into four groups based on the diagnosis of PCOS; 2 case groups and 2 control groups. Group 1 were non-obese PCOS subjects with body mass index (BMI) <25 kg/m2. Group 2 were obese PCOS subjects with BMI >25 kg/m2. Control groups were selected as; group 3 were non-obese control group with BMI <25 kg/m2. Group 4 were obese control group with BMI >25 kg/m2. Results: Adiponectin was significantly lower in group 1 than group 3 and 4 (P2 and P3 <0.001). While it was significantly lower in group 2 than group 1, 3 and 4 and was significantly lower in group 4 than group 3 (P1 = 0.021, P4 and P5 <0.001). Conclusion: Serum adiponectin level may be taken into consideration as a biomarker for confirmation of PCOS diagnosis. The relationship between adiponectin and BMI suggests that adiponectin could serve as a marker for disease risk and provide opportunity for earlier intervention.

scholarly journals Influence Of Different Methods Of Operative Treatment On Ovarian Reserve.

2012 ◽  
Vol 3 ◽  
Author(s):  
V Simrok ◽  
Simrok Starcheva
Keyword(s):  
Blood Flow ◽  
Surgical Treatment ◽  
Polycystic Ovary Syndrome ◽  
Operative Treatment ◽  
Ovarian Reserve ◽  
Polycystic Ovary ◽  
Ovarian Tissue ◽  
Reserve Estimation ◽  
Ovary Syndrome ◽  
Antral Follicles

This research paper presents the results of ovarian reserve estimation for 125 women with the Polycystic Ovary Syndrome (PCOS) who have undergone various methods of surgical treatment - resection of the ovaries, thermokauterisation and drilling by laser (Ho-Yag). Ovarian reserve was estimated according to the amount of antral follicles, level of follitropin and Müllerian inhibiting substance (MIS), also named anti-Müllerian hormone (AMH). Blood flow in ovarian tissue was also examined after various methods of surgical treatment. The study has shown that the gentlest method of surgical treatment is drilling by Ho-Yag laser, which is least likely to injure the tissue of ovaries, and also this method is most effective in enhancing and preserving ovarian reserve.

scholarly journals The relationship between Vitamin D deficiency and polycystic ovary syndrome

2020 ◽  
Vol 20 (4) ◽  
pp. 1880-6
Author(s):  
Feyzi Gokosmanoglu ◽  
Attila Onmez ◽  
Hasan Ergenç
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Vitamin D Deficiency ◽  
Polycystic Ovary ◽  
Serum Testosterone ◽  
Dehydroepiandrosterone Sulfate ◽  
Thyroid Function Tests ◽  
Ovary Syndrome ◽  
Group 2 ◽  
Group 1

Background: Vitamin D deficiency is frequently seen in patients with polycystic ovary syndrome (PCOS) and has been shown to exhibit multiple effects on the disease process. The purpose of this study was to investigate the role of vitamin D deficiency in complex PCOS pathophysiological pathways. Methods: Two hundred sixty-seven patients with PCOS were divided into two groups Group 1 with 25(OH)D3 deficiency, and Group 2 with normal 25(OH)D3. Biochemical and hormonal parameters (androgen hormones, gonadotropins, and thyroid function tests) were compared between the two groups. Results: Eighty-six percent of the patients (n=231) were in Group 1 and 14% (n=36) in Group 2. Statistically signifi- cantly higher concentrations of serum testosterone, dehydroepiandrosterone-sulfate and LH were determined in Group 1 (p<0.05). 25(OH)D3 concentrations were negatively correlated with body mass index (r=−0.459), serum testosterone (r =−0.374) and dehydroepiandrosterone-sulfate levels (r=−0.418); (all; p< 0.05). Conclusion: The study findings show that low 25(OH)D3 levels are associated with high androgen levels in women with PCOS. Vitamin D deficiency should be considered as an additional risk factor in the development of PCOS. We think that providing vitamin D supplementation for women from identified deficiency areas can reduce the risk of PCOS development. Keywords: Polycystic ovarian syndrome; vitamin D deficiency; androgen hormones; testosterone.

scholarly journals Impact of Luteal phase clomiphene citrate on endometrial thickness and clinical pregnancy rates in women with polycystic ovary syndrome

2020 ◽  
Vol 11 (3) ◽  
pp. 158-161
Author(s):  
Elsayed Elshamy ◽  
Ayman Soliman
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Luteal Phase ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Clomiphene Citrate ◽  
Clinical Pregnancy ◽  
Ovary Syndrome ◽  
Clinical Pregnancy Rates ◽  
Group 2 ◽  
Group 1

Objective: To compare between luteal phase clomiphene citrate and second cycle day clomiphene citrate on the thickness of the endometrium and clinical pregnancy rates in women with polycystic ovary syndrome. Methods: a prospective observational study conducted on 196 women with Polycystic ovary syndrome divided into two groups: Group 1 (98 patients) received 100mg of clomiphene citrate daily for 5 days starting on second cycle day and Group 2 (98 patients) received 100mg of clomiphene citrate daily starting in the luteal phase before onset of withdrawal bleeding for 5 days. Treatment and follow up applied for three cycles. Outcome measures were collected and analyzed and women who got pregnant were followed until 12 weeks of pregnancy. Results: no significant differences between the two groups regarding pre-ovulatory endometrial thickness (8.3mm in group 1vs 8.8mm in group 2), number of mature follicles (1.62 in group 1vs 1.57 in group 2) and mid-luteal serum progesterone levels(14.63ng/ml in group 1vs 14.9ng/ml in group 2). 34 women (35%) got pregnant in group 1 and 37 women (38%) in-group 2 and three patients had miscarriage in each group without any statistical significance. Conclusion: the present study does not support luteal clomiphene citrate over second cycle day clomiphene citrate to induce ovulation in infertile women with polycystic ovary syndrome.

Sign in / Sign up

Export Citation Format

Share Document